United States · FDA National Drug Code directory
Ondansetron
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 63187-379_0259eb8a-602d-42c0-a4ea-ad936de76410
- Product NDC
- 63187-379
- Form
- TABLET, ORALLY DISINTEGRATING
- Composition / generic term
- Ondansetron
- Labeler
- Proficient Rx LP
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20100412
- Source listing expiry
- 20261231
Source-listed ingredients
- ONDANSETRON — 4 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 3 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (63187-379-03) · 63187-379-03
- 5 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (63187-379-05) · 63187-379-05
- 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (63187-379-06) · 63187-379-06
- 7 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (63187-379-07) · 63187-379-07
- 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (63187-379-10) · 63187-379-10
- 12 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (63187-379-12) · 63187-379-12
- 15 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (63187-379-15) · 63187-379-15
- 20 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (63187-379-20) · 63187-379-20
- 30 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (63187-379-30) · 63187-379-30
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →